Open Source Health and GeneYouIn Announce Advances in Fertility Care Using Personalized Medicine
Toronto, Ontario, Canada – January 27, 2015: Open Source Health Inc. (CSE:OSH), (Frankfurt:0OS), is leading the digital transformation of integrative medicine with its cloud-based healthcare platform. OSH puts control into the hands of women to educate, advocate and collaborate on their own healthcare and is pleased to announce the convergence of integrative medicine and personalized medicine in guiding treatment of the number one cause of infertility – Poly-Cystic Ovarian Syndrome (PCOS).
The page you were looking for could not be found.
Check the URL for errors.“This is very personal for me and I am committed to helping women get access to the latest advancements in reproductive medicine,“ states Sonya Satveit, Founder and CEO of Open Source Health Inc. “It is personalized medicine combined with an integrative approach that will drive our care programs, guide physicians and ultimately provide women with the best chance at a positive outcome.”
According to the World Health Organization 116 million women worldwide suffer with Poly-Cystic Ovarian Syndrome (PCOS), making it the leading endocrine disorder among women and the number one cause of female infertility. The first line of treatment involves lifestyle modifications, after which debate remains over the use of the two most common drugs, Metformin and Clomifene in dealing with the infertility that often accompanies PCOS.
“Personalized medicine allows physicians to work with their patients to uncover the best forms of treatment and mitigate risks with precautionary measures”, states Dr. Ruslan Dorfman, CEO and Founder of Genyouin Inc., a Toronto, Canada based company. “At GeneYouIn we are excited to be working with OSH to reach women with PCOS and provide them with state-of-the-art genomic sequencing technology specific to their needs.”
A simple and non-invasive genetic test can identify genetic variations in women with PCOS and help guide treatment in two ways. First, by identifying genetic variations, which can determine how well a woman will respond to Clomifene, a common pharmacologic treatment for women with infertility. Secondly, women with PCOS are already at high risk for miscarriage and by identifying specific genetic variations that put these women at higher risk for miscarriage, physicians can plan precautionary measures. A woman’s full genetic report, stored within the OSH platform, can assist physicians and patients in devising a personalized treatment plan, including preventative measures that are tailored based on their genetic makeup.
About GeneYouIn Inc.
GeneYouIn provides genetic testing and consulting services to Executive, Fertility and other specialty clinics, as well as to individuals. GeneYouIn’s products aim to inform clients, and their healthcare providers, about genetic variations that may affect drug response and inherited disease risks, to help optimize health management. To provide unique insights on an individual’s health, GeneYouIn developed innovative software solutions for pharmacogenetic genome annotation available for clinical diagnostic laboratories. A genetic test from GeneYouIn provides invaluable, actionable information about an individual’s genetic make-up enabling one to take targeted, pro-active steps towards a healthy and active life.
For more information, visit www.geneyouin.ca
About Open Source Health Inc.:
Open Source Health takes a truly patient-centered approach and is in the business of providing a real-time integrative healthcare solution for women in an open source architecture. Open Source Health Inc. is set to lead the current healthcare revolution by leveraging the latest trends in digital health, personalized health, social health, and participatory medicine.
For more information, visit www.opensourcehealth.com
For further information, please contact Investor Relations at Open Source Health Inc.
Toll Free: 1.866.403.1933
Forward Looking Statements
Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of Open Source Health Inc. (“OSH”), including, but not limited to, the impact of general economic conditions, industry conditions and the uncertainty of obtaining additional financing. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.
The forward-looking statements contained in this press release are made as of the date of this press release, and OSH does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.